Integrity Alliance LLC. Boosts Stock Holdings in Pfizer Inc. $PFE

Posted by Trevor Kearing on May 28th, 2026

Integrity Alliance LLC. boosted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 24.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,598 shares of the biopharmaceutical company’s stock after buying an additional 22,457 shares during the period. Integrity Alliance LLC.’s holdings in Pfizer were worth $2,829,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PFE. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank grew its position in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. grew its position in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after purchasing an additional 631,523 shares in the last quarter. Finally, HUB Investment Partners LLC grew its position in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE:PFE opened at $26.24 on Thursday. Pfizer Inc. has a 52 week low of $23.06 and a 52 week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $149.55 billion, a P/E ratio of 20.03 and a beta of 0.35. The stock’s fifty day moving average is $26.82 and its two-hundred day moving average is $26.27.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PFE. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Wednesday, February 4th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Guggenheim upped their price target on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Finally, Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.61.

View Our Latest Report on Pfizer

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer announced new late-stage trial activity for its infant pneumococcal vaccine and obesity drug berobenatide, reinforcing that the company is pushing to build future growth drivers beyond its aging portfolio. Pfizer’s Next-Gen Infant Pneumococcal Vaccine Trial: What Investors Should Watch Now
Positive Sentiment: BofA Securities raised its price target on Pfizer to $27 from $26 after strong first-quarter results and improved 2026 revenue/EPS estimates, signaling continued analyst confidence in the stock’s valuation. BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results
Positive Sentiment: Pfizer is also highlighting its obesity push with a new Phase 3 trial, which could add another major opportunity if results are favorable. Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial
Neutral Sentiment: Recent commentary says Pfizer is leaning on new launches, Seagen assets, and pipeline progress to offset looming loss-of-exclusivity pressure, but the patent cliff through 2030 remains a major overhang for investors. Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
Negative Sentiment: Broader industry coverage on the Eliquis patent cliff underscores the kind of revenue loss Pfizer and peers can face when exclusivity ends, keeping attention on the company’s future replacement pipeline. Thinning revenues: inside the $14bn Eliquis patent cliff

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.